New concepts in benzodiazepine therapy: Rebound anxiety and new indications for the more potent benzodiazepines

@article{Chouinard1983NewCI,
  title={New concepts in benzodiazepine therapy: Rebound anxiety and new indications for the more potent benzodiazepines},
  author={Guy Chouinard and Anne Labont{\'e} and R{\'e}jean Fontaine and Lawrence. Annable},
  journal={Progress in Neuro-Psychopharmacology and Biological Psychiatry},
  year={1983},
  volume={7},
  pages={669-673}
}

Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound.

  • G. Chouinard
  • Psychology, Medicine
    The Journal of clinical psychiatry
  • 2004
Although as a class benzodiazepines act rapidly and are well tolerated, their use presents clinical issues such as dependence, rebound anxiety, memory impairment, and discontinuation syndrome.

Efficacy of benzodiazepines in panic disorder and agoraphobia.

  • J. Ballenger
  • Psychology, Medicine
    Journal of psychiatric research
  • 1990

The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs.

  • G. Chouinard
  • Psychology, Medicine
    Journal of psychiatry & neuroscience : JPN
  • 2006
The initial clinical trials of fluoxetine and sertraline led to their approved indications in the treatment of obsessive-compulsive disorder, and the trials of gabapentin led to new indications in anxiety disorders (generalized anxiety, panic attack and social phobia) and sleep disorders (insomnia).

Attitudes toward benzodiazepines over the years.

  • J. Rosenbaum
  • Psychology, Medicine
    The Journal of clinical psychiatry
  • 2005
The intent of this article is to provide a historic overview of issues and to offer some general clinical principles to help minimize the risk of abuse and dependence with benzodiazepine use.

The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs

The initial clinical trials of fluoxetine and sertraline led to their approved indications in the treatment of obsessive–compulsive disorder, and the trials of gabapentin led to new indications in anxiety disorders (generalized anxiety, panic attack and social phobia) and sleep disorders (insomnia).

Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications

The present overview aimed at analyzing the literature to illustrate withdrawal after decrease, discontinuation, or switch of psychotropic medications based on the drug class, finding that benzodiazepines should be substituted by medications that cause less dependence such as antidepressants and antipsychotics runs counter the available literature.

A Guide to Benzodiazepine Selection. Part II: Clinical Aspects

  • E. TeboulG. Chouinard
  • Psychology, Biology
    Canadian journal of psychiatry. Revue canadienne de psychiatrie
  • 1991
To suit the specific needs of various clinical situations, selection of an appropriate benzodiazepine derivative should be based on consideration of their different pharmacokinetic and

The Benzodiazepines: Current Standards for Medical Practice

The benzodiazepines: public health, social and regulatory issues, international legislation and relation to the Convention on Psychotropic Substances 1971.

A Risk-Benefit Assessment of Pharmacological Treatments for Panic Disorder

No one line of treatment has been found to be superior, making a risk-benefit assessment of the treatments available useful for treating patients, and cognitive behavioural therapy as a supplement to drug therapy is effective.

References

SHOWING 1-10 OF 12 REFERENCES

Bromazepam and Diazepam in Generalized Anxiety: A Placebo‐Controlled Study with Measurement of Drug Plasma Concentrations

Bromazepam was found to be significantly more effective than diazepam with respect to the somatic anxiety factor and the total score for the Hamilton Anxiety Rating Scale and the fear/anxiety factor of the Patient's Self-Rating Symptom Scale.

Carbamazepine in manic-depressive illness: a new treatment.

The authors evaluated carbamazepine (Tegretol), a drug of choice for treatment of temporal lobe epilepsy, in a double-blind placebo-controlled trial in patients with manic-depressive illness. Seven

A comparison between bromazepam (Ro 5-3350, Lexotan) and diazepam (Valium) in anxiety neurosis. A controlled, double-blind clinical trial.

Bromazepam proved to be statistically significantly superior to diazepam when evaluated through patients' preferences, in particular in obsessive and phobic neurosis.

Antimanic effect of clonazepam.

Clonazepam was found to be significantly more efficacious than lithium in reducing manic symptoms despite the fact that during clonAZepam treatment less patients required PRNs of haloperidol, and may decrease the risk of tardive dyskinesia in manic patients.

Comparison of alprazolam, imipramine, and placebo in the treatment of depression.

In a six-week, double-blind multicenter comparison of alprazolam, imipramine hydrochloride, and placebo in the treatment of 723 patients with depression, the two active drugs were statistically more effective than placebo.

Benzodiazepine prescribing in a family medicine center.

We monitored benzodiazepine prescribing in a family medicine center for two years. A total of 1,886 prescriptions were written for four benzodiazepines in the following order of frequency: diazepam,

Multicenter double-blind efficacy and safety study comparing alprazolam, diazepam and placebo in clinically anxious patients.

  • J. Cohn
  • Psychology, Medicine
    The Journal of clinical psychiatry
  • 1981
Both alprazolam and diazepam were superior to placebo for the treatment of the clinical anxiety syndrome throughout a four-week double-blind multiclinic trial in 976 outpatients. At the fourth-week

Benzodiazepine binding sites: receptors or acceptors?

Therapeutic effect of valproate in mania.

Alprazolam in a biochemical model of depression.